Mental IllnessNCT06632756
Positive Psychology for Smoking Cessation
A study testing Individual and Group Treatment for Smoking Cessation in people with Mental Illness and Tobacco Dependence, run by Dartmouth-Hitchcock Medical Center at 1 site in United States.
Trial summary
This study will examine how Positive Psychotherapy (PPT) may help people interested in quitting smoking, quit. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Mental Illness, Tobacco Dependence
- What is being tested?
- Individual and Group Treatment for Smoking Cessation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteUnited States
- Study dates
- 10 Oct 2024to 30 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age 21+;
- Serious Mental Illness (SMI) diagnosis;
- smoking ≥10 CPD;
- breath CO ≥10;
- desire to quit in the next month;
- willingness to use NRT daily;
- English speaking and literate to engage in the treatment.
Who cannot join
- legal guardian;
- active substance use disorder.
Trial locations and contacts
1 site in 1 country.
United States1 site
The Mental Health Center of Greater Manchester
Manchester, New Hampshire, 03103
About this study
Official title: Positive Psychotherapy for Smoking Cessation: A Focus on Strengths to Improve Self-efficacy and Enable Successful Quitting Strategies
This study will examine how Positive Psychotherapy (PPT) may help people interested in quitting smoking, quit.
Read the detailed description
This project aims to adapt the Positive Psychotherapy (PPT) practice for smoking cessation in adults with severe mental illness (SMI), testing its usability, feasibility, and acceptability in a mixed-methods feasibility pilot study. Qualitative interviews will be conducted to obtain usability and acceptability input on the adapted PPT manual from 4-5 Peer Providers. Then, in partnership with The Mental Health Center of Greater Manchester (MHCGM), 6-8 adult smokers with SMI will be recruited who want to quit smoking in the next month and are willing to use nicotine replacement therapy (NRT). The 16-week PPT adaptation ("Positive Recovery for Smoking") will be tested progress on cessation assessed through interviewer-administered quantitative assessments at baseline, 8, and 16 weeks. Self-reported cigarettes per day (CPD) and carbon monoxide (CO) will be collected prior to each group treatment session. Informed by the weekly group check-in of cessation progress (quitting status), qualitative interviews will be conducted at 16 weeks to obtain a more nuanced description of the uptake of the intervention, successful quitting strategies, and barriers to cessation with this new method. The manual and materials will be adapted based on the feedback from the first group and another group of 6-8 participants will be recruited to receive the refined intervention and protocol. The result of this feasibility pilot will provide data on the adapted PPT's feasibility and acceptability, alongside a deep description of strategies used and why and how the treatment was perceived as useful or not to the enrolled participants.
- Conditions
- Mental Illness, Tobacco Dependence
- Being tested
- Individual and Group Treatment for Smoking Cessation
- Medical subject headings
- Mental Disorders, Tobacco Use Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Individual and Group Treatment for Smoking CessationBehavioural
Positive psychology-based individual treatment and groups
| Study group | Role | What they receive |
|---|---|---|
| Positive Recovery Smoking Cessation (Individual and Group) | Experimental | The "Positive Recovery for Smoking" program is a 16-week treatment that focuses on the use of identifying signature character strengths and identifying, creating, and enjoying positive life events to facilitate recovery from smoking addiction. The first 4 individual sessions will focus on a self-evaluation of strengths and a focus on the individuals top 5 "signature strengths". The participants will then learn about how their signature strengths currently help them function and when and how they can use these strengths to recover from smoking.
The group sessions will begin at 5 weeks (following 4 individual sessions) - sessions are structured to begin with a check-in where patients identify their most used signature strengths and take inventory of their smoking and cessation efforts from the past week. We will then support participants in their efforts to learn new ways to navigate positive recovery. Receives: Behavioral: Individual and Group Treatment for Smoking Cessation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Abstinence from Smoking
At least 20% of participants will achieve abstinence (0 cigarettes per day and CO less than 6) at 16 weeks.
Measured: baseline to 16 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2024
- Study start10 Oct 2024
- Primary completion30 Sep 2025
- Study completion30 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mental IllnessStudies of the same condition, open and under way.
- More trials run by Dartmouth-Hitchcock Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Joelle Ferron, Dartmouth-Hitchcock Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06632756
- Sponsor's protocol ID
- 2202130-2
- Status last verified
- Dec 2025
- First submitted
- 7 Oct 2024
- Last updated
- 18 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Positive Psychotherapy for Smoking Cessation: A Focus on Strengths to Improve Self-efficacy and Enable Successful Quitting Strategies
- ClinicalTrials.gov ID
- NCT06632756
- Acronym / sponsor ID
- 2202130-2
- Conditions
- Mental Illness, Tobacco Dependence
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Dartmouth-Hitchcock Medical CenterUniversity, hospital or other
- Study start
- 10 Oct 2024 (actual)
- Primary completion
- 30 Sep 2025 (actual)
- Study completion
- 30 Sep 2025 (actual)
- First posted
- 9 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will examine how Positive Psychotherapy (PPT) may help people interested in quitting smoking, quit.
Detailed description
This project aims to adapt the Positive Psychotherapy (PPT) practice for smoking cessation in adults with severe mental illness (SMI), testing its usability, feasibility, and acceptability in a mixed-methods feasibility pilot study. Qualitative interviews will be conducted to obtain usability and acceptability input on the adapted PPT manual from 4-5 Peer Providers. Then, in partnership with The Mental Health Center of Greater Manchester (MHCGM), 6-8 adult smokers with SMI will be recruited who want to quit smoking in the next month and are willing to use nicotine replacement therapy (NRT). The 16-week PPT adaptation ("Positive Recovery for Smoking") will be tested progress on cessation assessed through interviewer-administered quantitative assessments at baseline, 8, and 16 weeks. Self-reported cigarettes per day (CPD) and carbon monoxide (CO) will be collected prior to each group treatment session. Informed by the weekly group check-in of cessation progress (quitting status), qualitative interviews will be conducted at 16 weeks to obtain a more nuanced description of the uptake of the intervention, successful quitting strategies, and barriers to cessation with this new method. The manual and materials will be adapted based on the feedback from the first group and another group of 6-8 participants will be recruited to receive the refined intervention and protocol. The result of this feasibility pilot will provide data on the adapted PPT's feasibility and acceptability, alongside a deep description of strategies used and why and how the treatment was perceived as useful or not to the enrolled participants.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Positive Recovery Smoking Cessation (Individual and Group) | Experimental | Behavioral: Individual and Group Treatment for Smoking CessationThe "Positive Recovery for Smoking" program is a 16-week treatment that focuses on the use of identifying signature character strengths and identifying, creating, and enjoying positive life events to facilitate recovery from smoking addiction. The first 4 individual sessions will focus on a self-evaluation of strengths and a focus on the individuals top 5 "signature strengths". The participants will then learn about how their signature strengths currently help them function and when and how they can use these strengths to recover from smoking. The group sessions will begin at 5 weeks (following 4 individual sessions) - sessions are structured to begin with a check-in where patients identify their most used signature strengths and take inventory of their smoking and cessation efforts from the past week. We will then support participants in their efforts to learn new ways to navigate positive recovery. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- age 21+;
- Serious Mental Illness (SMI) diagnosis;
- smoking ≥10 CPD;
- breath CO ≥10;
- desire to quit in the next month;
Key exclusion criteria (2 listed)
- legal guardian;
- active substance use disorder.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Individual and Group Treatment for Smoking CessationPositive psychology-based individual treatment and groups | Behavioural | Positive Recovery Smoking Cessation (Individual and Group) |
Primary outcome
Abstinence from Smoking
Time frame: baseline to 16 weeks
At least 20% of participants will achieve abstinence (0 cigarettes per day and CO less than 6) at 16 weeks.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Mental Illness
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Enrolling by invitationPhase 3
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
ADHD
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Individual and Group Treatment for Smoking Cessation in people with Mental Illness and Tobacco Dependence, run by Dartmouth-Hitchcock Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Abstinence from Smoking (time frame: baseline to 16 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2025.